PCVX

Vaxcyte is a clinical-stage vaccine company developing next-generation pneumococcal conjugate vaccines. It has no product revenue, and the loss profile is large and widening: a net loss of -$767M in FY2025 (worse by 65.2%), an operating loss of -$924M, and diluted EPS of -$5.63. R&D spending surged 66.6% to $794M as the company funds its late-stage clinical programs, and losses have escalated every year shown (-$100M in FY2021 to -$767M in FY2025), with an accumulated deficit of -$2.15B. There is simply no earnings or revenue base on which to underwrite the stock — its value rests entirely on clinical-trial outcomes.

The balance sheet is the one genuine strength and the reason this is an avoid rather than an outright distress case. Total equity is $2.69B with minimal liabilities (0.12x liabilities/equity), and current assets of $1.63B (largely marketable securities beyond the $174M cash line) provide a multi-year runway against the burn. That funding cushion buys time, but it is being consumed quickly: operating cash flow was -$656M, cash fell 55.2%, and the share count rose 11.8% as the company raises capital — ongoing dilution that will likely continue until (and unless) a product is approved and commercialized.